The Medicare Prescription Drug Rebate Rule PCMA Urges Congress to Permanently Repeal Rebate Rule This Year The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement on the Pennsylvania Auditor General’s report, “Bringing Transparency & Accountability to Drug Pricing:” “The Pennsylvania Auditor General has released yet another biased report on pharmacy benefit managers (PBMs).
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. All that Glitters is Not Gold… It’s true,
COVID-19: Frequently Asked Questions PBMs have substantial experience helping patients get the drugs and vaccines they need, including in times of crisis. PBMs are taking action to help educate the patients we serve about the safety and efficacy of authorized
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress considers passing misguided proposals in the new year that will undermine the critical flexibility and
The new Biden administration has started off strong, taking a thoughtful approach to any number of critical health care issues and pulling back a number of new regulations to take a fresh look at these public policy issues. To avoid
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate levels over a five-year period from 2012 to 2017. In addition, the study analyzes a number of Medicare Part B
©2024 PCMA. All Rights Reserved.
